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Introduction
The traditional standard of care for patients with invasive
breast cancer is to perform level I and level II axillary lymph
node dissection (ALND).1 However, most breast cancer cen-
tres in the USA are currently adopting selective sentinel lym-
phadenectomy (SSL) as a staging procedure, especially when
they have accumulated extensive experience with a false-
negative rate lower than 5–10%. Thus, SSL staging of primary
breast cancer is rapidly evolving into the standard of care for
breast cancer in the USA. It is generally accepted that, if the
false-negative rate can be maintained at 5% or lower, SSL as
a staging procedure is definitely preferred to ALND, which
may be associated with increased morbidity.2 Indeed, the re-
cent 6th edition of the American Joint Committee on Cancer
(AJCC) recommendations have incorporated sentinel lymph
node (SLN) status in the staging of breast cancer.3
Development of SSL for breast cancer
Using melanoma as a model, Morton et al were the first to
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establish the physiological role of the SLN as the first guardian
lymph node for melanoma metastasis.4 Giuliano et al applied
the melanoma SLN concept to breast cancer and, in 1994, they
published the initial report of the use of a vital blue dye for
intraoperative lymphatic mapping and SSL for invasive breast
cancer.5 Since then, numerous studies have confirmed the
concept of SLN in breast cancer.6
Although Giuliano showed an excellent harvesting rate of
96% using the blue dye technique,7 most other studies have
reported an overall rate of about 80%.6,7 With the use of radio-
tracer and preoperative lymphoscintigraphy, the rate of
harvesting the SLN can be increased to almost 95%.6 To date,
there is no standard among investigators with respect to
particle size, time of injection and volume of injection for
radiotracer and the technique of preoperative lymphoscinti-
graphy and choice of blue dye versus radiotracer.
Reviews of the lymphatic system of the breast8–10 show a
well-structured system based on postmortem injection of
colloid gold particles,11,12 and on information collected from
axillary lymph nodes from mastectomy specimens.8 The
parenchymal lymphatic system is connected through a net-
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work to the cutaneous and periareolar lymphatic channels
leading to the corresponding SLN. Thus, if the entire path-
way is connected, any point of injection in the lymphatic net-
work, such as intradermal injection over the skin of the breast
lesion, periareolar or subareolar injection, would probably
drain to the same SLN as if injected peritumourally. Since
the lymphatic channels are much richer at the cutaneous
level than in the peritumoural site, it is much easier to “light
up” the SLN by lymphoscintigraphy using intradermal or
periareolar injections. Indeed, Linehan et al showed that
the dermal and parenchymal lymphatics of the breast drain
to the same SLN in most patients.13 Likewise, Klimberg et al
showed that subareolar injection of technetium is as accu-
rate as peritumoural injection of blue dye.14 The reliability
of subareolar injection has been further confirmed by Kern
and Rosenberg.15 Based on dynamic and static images to
match or mismatch the hot spots visualized by both tech-
niques, Roumen et al used both peritumoural and intrader-
mal radiotracer injections either in the skin overlying the
tumour or periareolarly in the quadrant of the tumour.16
With few exceptions, the skin and peritumoural injections
resulted in the same axillary sentinel node.16
Based on the classic description of the breast lymphatic
system8 and recent studies by Linehan et al, Klimberg et al,
Kern and Rosenberg and Roumen et al,13–16 concordancy be-
tween peritumoural and dermal/periareolar lymphatic drain-
age to the same SLN is probably the rule. A recent multicentre
study showed that intradermal injection of radioactive colloid
significantly improves the SLN identification rate.17 We have
observed that after blue dye injection into peritumoural areas,
the blue dye migrates to the surface above the tumour site
and then goes to the axillary SLNs, attesting to the fact that
lymphatic channels in the breast are connected between the
parenchymal tissue and the overlying skin.18 Therefore, we
feel that it is quite appropriate to simplify the technique by
using intradermal injections over the tumour or periareolar-
ly in the quadrant of the tumour to facilitate preoperative
lymphoscintigraphy and intraoperative harvesting of the
axillary SLNs.
Both peritumoural and intradermal/subareolar injections
will result in an excellent match of the axillary SLN, but the
internal mammary lymph nodes are not visualized with intra-
dermal/subareolar injections.15,19 On the other hand, peritu-
moural injection may identify an internal mammary chain.20
Although the lymphatic mapping technique for internal mam-
mary nodes has recently been described,21 the issue of identi-
fying internal mammary nodes remains controversial,20,22 and
only prospective studies will address the significance of the
internal mammary lymph nodes.22 In general, if the axillary
lymph node basin is negative, the internal mammary nodes are
negative. Therefore, if the axillary SLN is negative, the internal
mammary nodes may be assumed to be negative.
SSL technique
The steps for SSL for breast cancer are summarized in Table 1.
Technical details have been published elsewhere.7,18,23 Valu-
able tips for SSL for breast cancer from several experts in
the USA may be summarized. If blue dye is used, it is impor-
tant to inform patients that their urine and stool may be blue,
to allay any fears they may experience. Blue dye allergic reac-
tions may occur:24 the injection site should be watched for
wheal reactions and the pulse and blood pressure monitored
during the procedure. It is important not to mix isosulfan blue
dye, Tc99m-labelled sulfur colloid or local anaesthetics in the
same syringe for combined injection; a precipitate will form,
and neither dye nor colloid will migrate, leading to mapping
failure. According to Giuliano’s blue dye method, 5 mL of iso-
sulfan blue dye should be injected intraparenchymally along
the axillary side of the tumour or biopsy site.6 Continuous,
firm manual compression of the breast over the injection site
should be applied in a gentle rotating motion for 5 minutes.
The incision is made 1 cm below the axillary hairline and tak-
en to the depth of the clavipectoral fascia, to look for a blue
channel leading to the SLN. Usually, the blue lymph node is in
the junction between the tail end of the breast and the lower
level of the axilla. Often, there will be a blue lymphatic run-
ning longitudinally towards the lower aspect of level I into a
lymph node about 2 cm or less underneath the skin, below the
Table 1. Steps for selective sentinel lymphadenectomy
1. Preoperative lymphoscintigraphy
– Injection of sulfur colloid
– Identification of lymphatic basins
2. Anaesthesia: local vs general
3. Intraoperative mapping
– Lymphazurin injection
– Intraoperative mapping with hand-held gamma counter
4. Identification of SLNs
5. Pathological identification of SLNs by H&E and IHC
SLN = sentinel lymph node; H&E = haematoxylin and eosin; IHC =
immunohistochemistry.
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subcutaneous tissue and below the layer of the superficial
fascia. The lymphatic channel may not be present proximal to
the lymph node and, therefore, if dissection is made at this
level, the blue lymphatics may not be seen. Further proximal
and deeper dissection, either towards the apex of the axilla or
the medial chest wall, will not reveal the SLN. Therefore, when
such deep levels are reached, it is important to reflect that the
incision may be too high above the level of the blue lymphatics.
Dissection can be traced back to find the blue lymphatics and
to secure the blue lymph node in the lower axilla. According to
Cox et al’s experience, approximately 94% of all SLNs in breast
cancer are found within a 5-cm circle;23 the centre-point is
marked by the inferior border of the hairline in the axilla and
a line drawn through the centre of the hair-bearing area, along
the axis of the axilla. This point is situated where the lateral
branch of the third intercostal nerve crosses the central axillary
vein, beneath the clavipectoral fascia. Using a hand-held gamma
probe, Reintgen found that the SLN is found when there is an
area of clearly diminished counts between the injection site
and the “hot spot” in the nodal basin.23 According to Leong,
the SLN is usually found beneath the clavipectoral fascia.18
Therefore, tunnelling dissection without raising flaps should
be used to gain access to the fascia and incise it. The SLN
is usually located using a hand-held gamma probe and/or
visualizing blue lymphatics underneath the fascia within the
axillary tissue. Good surgical techniques should be applied
with good retraction and caution. Dissection should be lim-
ited around the SLN to avoid injury to vessels and nerves. All
lymphatic channels should be clipped. According to the in-
verse square law, radioactivity increases proportionally to the
square of the radius as the gamma probe approaches the “hot”
SLN. “Shine through” occurs and can be problematic. It is
advisable to turn the probe away from the injection site to
localize the SLN. Digital exploration should always be done
prior to the completion of SSL to make sure that no suspicious
or enlarged lymph nodes are retained in the surgical bed as
blue dye or radiocolloid may not enter a grossly metastatic
lymph node. Blue nodes, “hot” nodes (3× greater than the
tissue background), nodes with in situ counts of more than 10%
of the hottest node ex vivo count,25 and indurated or suspi-
cious nodes, even if not blue or “hot”, should be considered
SLNs.
Complications
The incidence of adverse reactions to blue dye is estimated to
be about 0.7%, as reported for melanoma patients.26 Recently,
adverse reactions to blue dye have also been reported in about
1.1%27 to 1.6%24 of breast cancer SLN procedures. Adverse
reactions are encountered in both melanoma and breast can-
cer cases, as shown by a national survey conducted by the
author.28 Surgical and anaesthesia complications are consis-
tent with the procedure performed. Statistics are being col-
lected in a prospective fashion on nerve injury, wound infec-
tion, seroma, lymphoedema and so forth.
SSL vs ALND controversies
To settle the controversies surrounding ALND, a prospective
randomized study sponsored by the National Cancer Institute
and the American College of Surgeons Oncology Group has
been initiated, entitled, “A randomized trial of axillary node
dissection in women with clinical T1–2N0M0 breast cancer
who have a positive SLN” (website: http://www.acosog.org).
There would be no significant benefit of ALND in patients
with a negative axilla. Therefore, only when an SLN is positive
for micrometastasis are patients with primary breast cancer
randomized to either an ALND or no ALND followed by ap-
propriate radiation and systemic therapy. If the outcome of
the study shows that there is no difference in the two arms,
then the treatment with less morbidity and fewer compli-
cations, presumably SSL, would be the procedure of choice.
It is possible that after the removal of a positive SLN, no fur-
ther surgery is needed for women with regional nodal meta-
stasis from early breast cancer.
A slightly different randomized clinical trial, “A ran-
domized, phase III clinical trial to compare sentinel node
resection to conventional axillary dissection in clinically node-
negative breast cancer patients”, has been launched by The
National Surgical Adjuvant Breast and Bowel Project.29 In
order to make these clinical studies successful, a high standard
of accuracy must be achieved by the multidisciplinary ap-
proach between surgeons, nuclear medicine physicians and
pathologists. Indeed, a surgeon must be qualified by perform-
ing 30 SLN dissections followed by complete lymph node
dissection, to establish that the surgeon’s false-negative rate
is less than 10%.30,31
Consensus statement from the American
Society of Breast Surgeons
In November 2002 and October 2003, the American Society of
Breast Surgeons issued guidelines, as detailed in the following
sections, for SSL (website: http://www.breastsurgeons.org/).
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Indications and contradictions
In general, patients with invasive breast cancer should un-
dergo SSL as an initial staging procedure, provided that the
centre is well trained in a multidisciplinary approach. Other-
wise, SSL should be performed as part of a research pro-
tocol or be validated with an ALND. Contraindications for
SSL are listed in Table 2. SSL should be considered for patients
with ductal carcinoma in situ treated with mastectomy. The
appropriate surgical management of patients with breast can-
cer should include the option of SSL as a staging procedure.
Management of the axilla
For patients with a positive SLN not participating in a clinical
trial, a complete ALND should be performed. In cases of
micrometastasis, sound clinical judgement is encouraged as
the definition of the positive SLN is controversial.
Credentialling
The recommendation is that each surgeon performs 20 cases
of SSL in combination with ALND, or 20 SSL procedures with
mentoring to minimize the risk of false-negative results. The
use of mentoring, proctored cases and formal training in
accredited continuing medical education courses is thought
to reduce the personal case experience required to achieve
acceptable results. However, the effect of these approaches has
yet to be quantified.
Technique
A combination of technetium sulfur colloid and blue dye is
recommended as both tracers enhance the SLN identification
rate and lower the false-negative rate.
Axillary recurrence
Surgeons are encouraged to log their axillary recurrence rate
and to report to national registries and enrol patients in
clinical trials.
Further issues of credentialling
SSL is a minimally invasive staging procedure and, when
performed in lieu of ALND, is associated with potentially
less morbidity and enhanced staging. Although the accura-
cy of SSL has been validated in multiple studies, both single-
institution and multicentre trials, the exact criteria for
achieving such accuracy remain undefined. It is paramount
that the surgical community should make sure that surgeons
performing this procedure have gone through some didactic
training and proctoring. Although 30 cases of SSL followed
by ALND might have been appropriate at the inception of
this technique in the early 1990s,31 this approach is not prac-
tical because patients will be unwilling to undergo addition-
al procedures as the technique is widely available in most
major cancer centres in the USA. Further statistical estimation
makes the learning curve an illusion rather than reality.32
It is prudent and ethical for a surgeon to learn this technique
from scratch by taking a lymphatic mapping course, which
is being offered in major cancer centres in the USA on a
yearly basis. The next step will be to operate with an experi-
enced surgeon who uses these techniques on a routine ba-
sis. After several cases, the surgeon may want to pursue cases
alone with appropriate proctoring. When the surgeon feels
able to harvest the SLN in a reliable fashion and can honestly
tell the patient that he or she has acquired enough compe-
tence to perform the technique, the surgeon is ready to per-
form SSL unsupervised. Currently, there is no official cre-
dentialling process by which surgeons are qualified to under-
take the procedure. As mentioned above, the American So-
ciety of Breast Surgeons recommends that 20 cases is ap-
propriate. Recently, Simmons has published data to indi-
cate that 10 cases may be sufficient.33
For early breast cancers smaller than 1 cm, the positive SLN
rate in well-established series is relatively low.23,34,35 There-
fore, for new surgeons to learn SSL with a large proportion of
patients with small tumours of 1 cm or less, since the positive
rate will be low, it will take more patients to calculate their
false-negative rate. For a general surgeon to be able to get
20–25 patients, it would probably take more than a year, un-
less the primary practice of the surgeon was in breast cancer.
In reality, there is marked variation in the number of SSL
cases validated by an ALND before performing SSL only in
the USA.36 The most practical approach will be to use SSL
as a staging procedure for all patients with invasive breast
cancer and, if it is positive, to proceed with ALND unless
patients are under study protocols. It is imperative that sur-
Table 2. Contraindications for selective sentinel lymphadenec-
tomy
• Presence of suspicious palpable axillary lymph nodes
• History of prior breast radiation therapy
• History of either extensive prior breast surgery or axillary surgery
• Multifocal invasive disease
• Neoadjuvant chemotherapy
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geons become motivated and learn this technique and scrub-
in with their appropriate surgical peers who know this pro-
cedure well until they become comfortable. Further, the
“learning” surgeon should make sure that an experienced
surgeon is always available for immediate intraoperative
consultation if needed.
Clinical significance of micrometastasis in
SLNs
The clinical significance of the breast SLN remains to be
evaluated based on follow-up of breast cancer patients under-
going SSL and on patients being enrolled in clinical trials. In
the pre-SLN era, breast cancer micrometastasis was defined
as a focus of tumour in the draining lymph node not exceed-
ing 2.0 mm.37 In general, micrometastasis to regional nodes
had a poor prognosis.38–41 Some studies have shown a worse
outcome for patients with an immunohistochemistry (IHC)-
positive metastasis.42–46 However, these studies were per-
formed on lymph nodes from ALND rather than the SLNs.
The definition of micrometastasis is the same for SLNs.
Since the clinical outcome of micrometastasis, in particular
IHC-positive SLNs, is not well known, Ibarra cautioned not to
use across-the-board decisions to treat anyone based on an
IHC-positive micrometastasis in SLNs.47
Braun et al analysed micrometastasis in bone marrow
aspirates and level I axillary lymph nodes (n = 1,590) from 150
node-negative patients with stage I or II breast cancer by
immunocytochemical staining with monoclonal anticyto-
keratin (CK) antibodies.48 CK-positive cells in bone marrow
aspirates were present in 44 patients (29%), whereas only
13 patients (9%) had such positive findings in lymph nodes.
Only two patients had simultaneous microdissemination
to bone marrow and lymph nodes. Reduced 4-year distant
disease-free and overall survival were each associated with a
positive bone marrow finding (p = 0.032 and p = 0.014, respec-
tively) but not with lymph node micrometastasis. It should
be noted that SLNs were not harvested and compared to
bone marrow status. Since the incidence of metastasis has
been reported to increase in SLNs over regional nodes ob-
tained by routine ALND (42% vs 29%),49 further studies
should compare the clinical significance of micrometasta-
sis in SLNs and bone marrow. A prospective study under
the American College of Surgeons Oncology Group Z0010
protocol (http://www.acosog.org) will address the relevance
of micrometastasis to SLN and bone marrow in early breast
cancer with respect to clinical outcome.
Paradigm of metastasis in the sentinel
node era
There is a linear relationship between tumour size in breast
cancer and SLN status. Due to the accuracy of SSL as a staging
method, the 6th edition of the AJCC recommendations for
breast cancer have been revised with incorporation of the
SLN status.3 Metastatic breast cancer cells are generated as a
result of proliferation and early metastasis may occur in the
regional SLN. In general, the paradigm of metastasis for
breast cancer is characterized by proliferation and metasta-
sis to SLNs then to non-SLNs prior to systemic metastasis
(Figure 1). Occasionally, it is possible for tumour cells to
spread via systemic circulation to sites distant from the pri-
mary site. Patterns of metastasis with their corresponding
survival rates for breast cancer are shown in Figure 2. The
unresolved issue is at what critical point of that progression
can the cancer be arrested prior to metastasis either to SLNs
or systemic sites. If only SLNs are involved, the removal
of positive SLNs should render a cure. The threshold of tu-
mour burden in SLNs prior to systemic metastasis is yet to be
determined. In the future, molecular markers may further de-
fine subgroups, thereby identifying patients who would re-
quire either only SSL or completion ALND for their axillary
disease. It is reasonable to assume that a cancer’s metastatic
potential increases with proliferation; the process is progres-
sive. Most cases of breast cancer follow an orderly progression
of metastasis to the SLN, and a small subgroup of patients
may develop systemic dissemination without SLN involvement.
Figure 1. The paradigm of metastasis for breast cancer includes
local growth and proliferation with the resultant more aggressive
clones that metastasize to sentinel lymph nodes (SLNs) and subse-
quently to non-SLNs prior to systemic metastasis. Occasionally,
tumour cells may spread from the primary site, SLNs or non-SLNs
via systemic circulation to distant sites.
Local growth
Increase in size and grade
for breast cancer
SLN Systemic
Regional nodes
ASIAN JOURNAL OF SURGERY  VOL 27 • NO 4 • OCTOBER 2004 273
070/2001
■ SENTINEL LYMPHADENECTOMY FOR BREAST CANCER ■
Since treatments for metastatic cancer are still limited, it is
imperative for oncologists to detect and resect an early cancer
as soon as possible.51
Conclusion
The validation of the SLN concept in human solid cancers is
definitely a turning point in the management of human solid
cancers, in particular for melanoma and breast cancer. Al-
though the therapeutic role of SSL in breast cancer has not
been determined, the practical significance is that it is being
applied widely as a staging procedure so that a negative SLN
can spare a patient more extensive ALND with its associated
morbidity. If the SLN is negative, the negative predictive value
of the remaining nodal basin for breast cancer exceeds 95%.6
SSL selects out one or a few SLNs and permits more extensive
study of the nodes by the pathologist. Such extensive exami-
nation would not be practical for the many nodes yielded
by a standard ALND. For breast cancer, SSL is rapidly evolv-
ing into a standard approach in the United States without the
maturation of results from clinical trials.52
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